Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis

20252 citationsJournal Articlegreen Open Access

Authors

Bram Verstockt · KU Leuven

Dahham Alsoud · KU Leuven

Joep van Oostrom · Amsterdam Neuroscience

Sare Verstockt · KU Leuven

Jeff Smith · Mirati Therapeutics (United States)

Jack Stylli · Mirati Therapeutics (United States)

Sujay Singh ·

Abstract

This study underscores the importance of tissue tofacitinib levels in UC treatment efficacy, with pSTAT3 reduction serving as a potential marker of drug efficacy. RNA sequencing identified molecular pathways for potential biomarkers and novel therapeutic targets in tofacitinib non-responders.

Topics & Keywords

Inflammatory Bowel Disease Tuberculosis Research and Epidemiology Cytokine Signaling Pathways and Interactions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Crohn s and Colitis

Volume 19, Issue 5

DOI: 10.1093/ecco-jcc/jjaf063

Field-Weighted Citation Impact: 3.68